Profile
Anthony L. Boral is Executive Vice President-Clinical Development at Blueprint Medicines Corp. In his past career he occupied the position of Vice President-Oncology Clinical Research at Millennium Pharmaceuticals, Inc. and Executive Director-Oncology Clinical Research at Novartis Institutes for Biomedical Research, Inc. He received a doctorate from Albert Einstein College of Medicine, Inc. and an undergraduate degree from Wesleyan University.
Former positions of Anthony Boral
| Companies | Position | End |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 11/01/2021 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01/02/2015 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 01/10/2010 |
Training of Anthony Boral
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Albert Einstein College of Medicine, Inc.
Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
- Stock Market
- Insiders
- Anthony Boral
















